Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for chronic viral hepatitis

F Alvarez1

  • 1Division of Gastroenterology-Nutrition, Hôpital Sainte-Justine, Montreal, Que. alvarezf@ERE.UMontreal.ca

Clinical and Investigative Medicine. Medecine Clinique Et Experimentale
|October 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

(R)-Mandelonitrile Lyase, a Homolog of Pru du 10, Is a Major Peach Allergen.

Journal of investigational allergology & clinical immunology·2025
Same author

Comparative Passivation of Si(100) by H<sub>2</sub> and D<sub>2</sub> Atmospheres under Simultaneous Xe<sup>+</sup> Bombardment: An X-ray Photoelectron Spectroscopy Analysis.

Langmuir : the ACS journal of surfaces and colloids·2024
Same author

Prelacrimal window approach to the maxillary sinus: a systematic review and meta-analysis of the literature.

Rhinology·2024
Same author

The effects of gestational age on neonatal cholestasis: A retrospective cohort study.

Journal of neonatal-perinatal medicine·2024
Same author

R-mandelonitrile-lyase, homolog to Pru d 10, is a major peach allergen in peach allergic Spanish population.

Journal of investigational allergology & clinical immunology·2024
Same author

Corrigendum to "Menstrual cycle and exogenous attention toward emotional expressions" [Horm. Behav. 146 (2022) 105259].

Hormones and behavior·2023

Interferon alfa therapy can benefit select children with hepatitis B virus (HBV) infection, particularly those with high ALT levels and active inflammation. For hepatitis C virus (HCV), limited data suggest interferon alfa may improve outcomes in children.

Area of Science:

  • Hepatology
  • Virology
  • Pediatric Gastroenterology

Background:

  • Chronic hepatitis B (HBV) and C (HCV) infections pose risks of cirrhosis, liver failure, and hepatocarcinoma.
  • Interferon alfa is a potential therapeutic agent for viral hepatitis.
  • Limited data exist on interferon alfa efficacy in pediatric populations.

Purpose of the Study:

  • To evaluate the efficacy of interferon alfa in treating chronic hepatitis B and C in children.
  • To identify factors predicting treatment response in pediatric HBV and HCV infections.

Main Methods:

  • A study treated children with HBV using interferon alfa (6 MU/m2 thrice weekly for 6 months).
  • A pilot study treated children with HCV using interferon alfa (3 MU/m2 thrice weekly for 6 months).

Related Experiment Videos

  • Long-term follow-up assessed viral clearance, ALT normalization, and histological activity.

    • Main Results:

    • For HBV, interferon alfa accelerated replication clearance in a select group, with benefits predicted by high ALT, low HBV-DNA, and active inflammation.
    • For HCV, 90% of treated children achieved ALT normalization and reduced histological activity after 15 months.
    • Predictive factors for favorable response in adults were noted, but controlled studies are needed for pediatric HCV.

    Conclusions:

    • Interferon alfa therapy can benefit specific pediatric HBV cases.
    • Available data suggest potential efficacy of interferon alfa for pediatric HCV, possibly with better outcomes than adults.
    • Further randomized controlled trials are necessary to establish definitive indications for interferon alfa in children with HCV.